The company is committed to unlocking new frontiers in neuroscience and developing Usnoflast for patients with ALS
The company ensures a reliable and strong portfolio at competitive prices without compromising on excellent quality
SIM0500 is a humanized trispecific antibody that targets GPRC5D, BCMA, and CD3
Regulatory filings underway for a third indication for darolutamide in prostate cancer, for finerenone in a common form of heart failure, and acoramidis in transthyretin amyloid
Lonza to develop spray-dried formulations for an intranasally-delivered biologic for Iconovo at its Center of Excellence for bioavailability enhancement and inhaled delivery in Bend (US)
The primary objective of the study is to assess the safety and tolerability of SUVN-I6107 by monitoring adverse events (AEs), clinical laboratory, vital signs and electrocardiographs
Increases speed to market for drug developers working on nucleic acid therapeutics
The new brand name reflects the evolution from a generics-focused Contract Research Organization (CRO) to a drug development services enterprise
Hansoh Pharma has granted Merck an exclusive global license to develop, manufacture and commercialize HS-10535
Subscribe To Our Newsletter & Stay Updated
